NCT01187199View on ClinicalTrials.gov

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

August 19, 2010

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Advanced Cancer
Interventions
DRUG

Temsirolimus

Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.

DRUG

Bevacizumab

Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.

DRUG

Paclitaxel

Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.

DRUG

Sorafenib

Starting dose 200 mg by mouth daily for a 21 day cycle.

DRUG

Carboplatin

Starting dose AUC 2 by vein on day 1 of a 21 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER